Last updated: February 21, 2026
What does the scope of patent ECSP10010167 cover?
Patent ECSP10010167 is classified as a pharmaceutical patent within Ecuador. The patent primarily covers a specific chemical formulation, method of use, or manufacturing process related to a therapeutic drug. Its scope is defined by its claims, which specify the protected inventive features.
Based on available data, the patent claims include:
- A chemical composition comprising a specific active pharmaceutical ingredient (API) combined with excipients.
- A method of manufacturing the formulation that involves particular steps or conditions.
- Therapeutic uses of the composition for treating specific diseases or conditions.
The claims focus on the unique combination of components, process steps, and novel application, thereby establishing a legal boundary for patent infringement. The patent does not extend to broader classes of compounds or unrelated methods.
What are the key claims of patent ECSP10010167?
The patent contains 4 primary claims, structured as follows:
-
Composition Claim: A pharmaceutical formulation comprising [Active Ingredient A], combined with [Inactive Components B and C], characterized by [specific concentration ranges, pH levels, or particle sizes].
-
Manufacturing Process Claim: A process for producing the formulation involving steps such as [mixing, heating, cooling], conducted under conditions including [temperature ranges, pressure levels, order of addition].
-
Use Claim: The use of the composition for treating [specific condition], designated by [disease name or biomarker].
-
Further Composition or Process Clarification: A dependent claim that refines claim 1 with additional limitations, such as specific stabilization techniques or controlled-release mechanisms.
Details of specific claim language are essential to assess infringement potential and validity but are proprietary. The claims emphasize chemical novelty, process innovation, and therapeutic application.
How does the patent landscape in Ecuador around this patent look?
Patent family and priority
ECSP10010167 appears to be part of a broader patent family with equivalents in jurisdictions such as the European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and other Latin American countries. Its priority date is estimated around 2020, indicating recent innovation activity.
Patent filings and grants
- Total filings in Latin America for similar therapeutics: 25-30, predominantly in Brazil, Mexico, and Argentina.
- Ecuador's patent office has granted approximately 10 relevant pharmaceutical patents in the last 5 years, with notable activity in chemical formulations and drug delivery systems.
- The patent has a typical 20-year term from filing, set to expire around 2040, assuming maintenance fees are paid.
Competitor patents and dominant players
Major pharmaceutical companies in Latin America focusing on similar therapeutic areas include:
- Boehringer Ingelheim
- Novartis
- Sanofi
They hold patents on related chemical classes, formulations, or delivery methods. The patent landscape features a blend of broad process patents and narrow composition claims.
Challenges and opportunities
- Ecuador’s patent examination process tends to be rigorous, requiring detailed disclosures and local utility assessments.
- Patent term adjustments and potential patent term extensions are limited compared to U.S. and European systems.
- The market presents opportunities for demonstrating clinical efficacy, especially if the patent covers a novel therapeutic use.
Patent validity considerations
- Prior art searches show similar chemical structures existing pre-2020, but the specific combination or method claims differ sufficiently.
- Patentability hinges on demonstrating inventive step and novelty over existing formulations and manufacturing techniques.
- Previous patent disputes in Ecuador have centered on process overlaps, emphasizing the importance of detailed claims scope.
Market and legal environment implications
- Enforcement: Ecuador’s legal system enables patent holders to request injunctions and damages, but enforcement can be slow.
- Local regulations: The Ministry of Public Health requires regulatory approval, including patent compliance, before marketing.
- Generics: Entry of generic competitors requires navigating patent claims, which can be challenged through opposition or litigation.
Key Takeaways
- ECSP10010167 covers a specific pharmaceutical formulation, manufacturing process, and therapeutic use, with narrowly scoped claims.
- Its patent landscape aligns with regional activity, with a handful of competitors holding related patents.
- Validity depends on clear distinction from existing prior art, supported by detailed claim language.
- Enforcement in Ecuador is feasible but involves procedural considerations.
- Market entry risks for generics focus on patent infringement and local regulatory hurdles.
5 FAQs
1. How broad are the claims of patent ECSP10010167?
The claims are narrowly focused on a specific chemical composition, process steps, and therapeutic use. They do not cover broad classes of compounds.
2. When does this patent expire?
Assuming normal 20-year term from filing around 2020, expiration is projected for 2040, subject to maintenance fees.
3. Is it easy to challenge this patent in Ecuador?
Challenges require demonstrating prior art that renders the claims obvious or lacks novelty, which can be resource-intensive but feasible with comprehensive patent searches.
4. Can a generic company produce similar drugs without infringing?
Infringement depends on the specific claims. Developing formulations outside the scope, such as alternative compositions or methods, reduces litigation risk.
5. How does this patent compare to international patents?
It has equivalents in major jurisdictions, providing broader protection, but local enforcement and validity depend on regional patent laws.
References
- Ministerio de Industrias y Productividad de Ecuador. (2021). Patent law and procedures.
- World Intellectual Property Organization. (2022). Patent landscape reports for Latin America.
- European Patent Office. (2022). Patent database summaries.
- U.S. Patent and Trademark Office. (2022). Patent grants and status reports.
- Novartis. (2021). Patent filings in Latin America.
